Clinical activity in a phase 1 study of blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (AdvSM)

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: c7e9c67ae2da4219d5983ac8f48d8df45a559796
First added on: Feb 08, 2025